Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICOVER-60: CHOP-14 +/- Rituximab in Elderly Aggressive NHL
NCT00052936Phase 3Completed
- Sponsor
- German High-Grade Non-Hodgkin Lymphoma Study Group
- Start
- Jan 2001
- Primary completion
- Aug 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rituximab in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by German High-Grade Non-Hodgkin Lymphoma Study Group. Primary endpoint: Time to Treatment Failure at 3 years. Started Jan 2001; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00052936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052936.